{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:46:23Z","timestamp":1794541583342,"version":"4.9.1"},"reference-count":39,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"INTERREG VA Programme, managed by the Special EU Programmes Body","award":["BREATH (INT-VA\/045)"],"award-info":[{"award-number":["BREATH (INT-VA\/045)"]}]},{"DOI":"10.13039\/100017546","name":"Boston Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["Proximity to Discovery grant (MC_PC_16083; Queen"],"award-info":[{"award-number":["Proximity to Discovery grant (MC_PC_16083; Queen"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2024,9,13]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Cystic fibrosis transmembrane conductance regulator (CFTR) triple modulator therapy, elexacaftor\u2013tezacaftor\u2013ivacaftor (ETI) has transformed care for people with cystic fibrosis (CF) who have eligible mutations. It is, however, not curative. Response to treatment also varies and lung disease, although slowed, remains progressive. We have previously demonstrated inhibition of the epithelial sodium channel (ENaC) by selective furin inhibition to be an alternative, mutation-agnostic approach that can enhance airways hydration and restore mucociliary transport (MCT) in CF. Inhibition of furin therefore, offers a potential therapeutic strategy for those ineligible, intolerant or nonresponsive to ETI and may provide a further opportunity for clinical benefit for those currently treated with ETI. The aim of this study was to determine the impact of furin inhibition on ETI responses to assess its utility as an adjunct therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Differentiated primary CF human bronchial epithelial cells (HBECs) were treated with the highly selective furin inhibitor BOS-318 and with ETI. Ion channel function was measured using a 24-channel Transepithelial Current Clamp (TECC-24) system and airways surface hydration was investigated by measuring airway surface liquid (ASL) height and MCT rate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The presence of BOS-318 had no effect on the ability of ETI to stimulate CFTR-mediated Cl<jats:sup>\u2212<\/jats:sup>secretion but contributed a reduced Na<jats:sup>+<\/jats:sup>transport<jats:italic>via<\/jats:italic>robust inhibition of ENaC. This altered ion transport profile effected an improved ASL height and MCT rate, which were significantly greater than improvements observed with ETI alone, demonstrating the benefits of the dual approach.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Selective furin inhibition has the potential to further improve clinical outcomes for all people with CF and offers opportunity as an adjunct to improve responses to currently available CFTR modulator therapies.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00445-2024","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T11:00:19Z","timestamp":1727434819000},"page":"00445-2024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["BOS-318 treatment enhances elexacaftor\u2013tezacaftor\u2013ivacaftor-mediated improvements in airway hydration and mucociliary transport"],"prefix":"10.1183","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9248-5409","authenticated-orcid":false,"given":"Lisa E.J.","family":"Douglas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8599-5198","authenticated-orcid":false,"given":"James A.","family":"Reihill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1923-0610","authenticated-orcid":false,"given":"S. Lorraine","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"2025030304054512000_11.1.00445-2024.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.8120"},{"key":"2025030304054512000_11.1.00445-2024.2","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.jcf.2017.10.006","article-title":"Ion channels as targets to treat cystic fibrosis lung disease","volume":"17","author":"Martin","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2025030304054512000_11.1.00445-2024.3","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacftor\/ivacaftor in people with cystic fibrosis","volume":"205","author":"Nichols","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2025030304054512000_11.1.00445-2024.4","doi-asserted-by":"crossref","first-page":"e139983","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"2025030304054512000_11.1.00445-2024.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202110-2249OC"},{"key":"2025030304054512000_11.1.00445-2024.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2025030304054512000_11.1.00445-2024.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202011-4153OC"},{"key":"2025030304054512000_11.1.00445-2024.8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jcf.2022.01.012","article-title":"Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis","volume":"21","author":"Martin","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025030304054512000_11.1.00445-2024.9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00946-2020"},{"key":"2025030304054512000_11.1.00445-2024.10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/genes12030453","article-title":"Modulation of ion transport to restore airway hydration in cystic fibrosis","volume":"12","author":"Reihill","year":"2021","journal-title":"Genes (Basel)"},{"key":"2025030304054512000_11.1.00445-2024.11","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C400080200"},{"key":"2025030304054512000_11.1.00445-2024.12","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C400460200"},{"key":"2025030304054512000_11.1.00445-2024.13","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.200709781"},{"key":"2025030304054512000_11.1.00445-2024.14","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M610636200"},{"key":"2025030304054512000_11.1.00445-2024.15","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00435.2004"},{"key":"2025030304054512000_11.1.00445-2024.16","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.chembiol.2022.02.001","article-title":"A highly selective, cell-permeable furin inhibitor BOS-318 rescues key features of cystic fibrosis airway disease","volume":"29","author":"Douglas","year":"2022","journal-title":"Cell Chem Biol"},{"key":"2025030304054512000_11.1.00445-2024.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201511-2216OC"},{"key":"2025030304054512000_11.1.00445-2024.18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1807120"},{"key":"2025030304054512000_11.1.00445-2024.19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0904709106"},{"key":"2025030304054512000_11.1.00445-2024.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2025030304054512000_11.1.00445-2024.21","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2018.1501361"},{"key":"2025030304054512000_11.1.00445-2024.22","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00429-2020"},{"key":"2025030304054512000_11.1.00445-2024.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00746-2021"},{"key":"2025030304054512000_11.1.00445-2024.24","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1569-1993(20)30258-7","article-title":"ETD001: a long-acting and safely inhaled ENaC blocker to enhance mucociliary clearance","volume":"19","author":"Danahay","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2025030304054512000_11.1.00445-2024.25","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0256-2022"},{"key":"2025030304054512000_11.1.00445-2024.26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31499"},{"key":"2025030304054512000_11.1.00445-2024.27","doi-asserted-by":"crossref","first-page":"31831","DOI":"10.1016\/S0021-9258(18)31770-8","article-title":"Furin activates Pseudomonas exotoxin A by specific cleavage in vivo and in vitro","volume":"269","author":"Inocencio","year":"1994","journal-title":"J Biol Chem"},{"key":"2025030304054512000_11.1.00445-2024.28","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00128-22"},{"key":"2025030304054512000_11.1.00445-2024.29","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21079"},{"key":"2025030304054512000_11.1.00445-2024.30","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21430"},{"key":"2025030304054512000_11.1.00445-2024.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2004.04.026"},{"key":"2025030304054512000_11.1.00445-2024.32","doi-asserted-by":"crossref","first-page":"L456","DOI":"10.1152\/ajplung.00530.2017","article-title":"Subacute TGF\u03b2 expression drives inflammation, goblet cell hyperplasia, and pulmonary function abnormalities in mice with effects dependent on CFTR function","volume":"315","author":"Kramer","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2025030304054512000_11.1.00445-2024.33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063167"},{"key":"2025030304054512000_11.1.00445-2024.34","doi-asserted-by":"publisher","DOI":"10.1513\/pats.2306014"},{"key":"2025030304054512000_11.1.00445-2024.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907153410304"},{"key":"2025030304054512000_11.1.00445-2024.36","first-page":"L22","article-title":"Linking increased airway hydration, ciliary beating, and mucociliary clearance through ENaC inhibition","volume":"308","author":"\u00c5strand","year":"2015","journal-title":"Am J Phys Lung Cell Mol Phys"},{"key":"2025030304054512000_11.1.00445-2024.37","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.3390\/ijms21072386","article-title":"TMEM16A: an alternative approach to restoring airway anion secretion in cystic fibrosis?","volume":"21","author":"Danahay","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025030304054512000_11.1.00445-2024.38","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.3390\/ijms21072557","article-title":"Pharmacological inhibition and activation of the Ca(2+) Activated Cl(\u2212) Channel TMEM16A","volume":"21","author":"Centeio","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025030304054512000_11.1.00445-2024.39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008680"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00445-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T12:08:20Z","timestamp":1741003700000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00445-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2,24]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1183\/23120541.00445-2024"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00445-2024","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1183\/23120541.00445-2024.supp1","asserted-by":"subject"}]},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]}}}